0 +
Instruments in the field
0 +
Countries
0 +
Labs

We proudly present the breakthrough research our collaborators are producing and publishing. Learn how researchers and scientists are advancing discovery with the help from our products and solutions.

Mass produced stem cells:
A gateway to personalized medicine​

Ronawk T-blocks are disrupting the industry by enabling the production of adult stem cells in large quantities.

The study of adult stem cells has increased exponentially because of recent technological innovations in the life sciences, especially within the field of bioprinting. The array of applications under consideration runs the gamut—from reversing baldness to managing diabetes to transplanting personalized bioprinted organoids.

With the latter, researchers are envisioning culturing a patient’s own adult stem cells to create viable organoids that could be transplanted into the patient with no need for the long-term immunosuppressant drugs they would have taken with a donated organ.

The study of adult stem cells has increased exponentially because of recent technological innovations in the life sciences, especially within the field of bioprinting. The array of applications under consideration runs the gamut—from reversing baldness to managing diabetes to transplanting personalized bioprinted organoids.

With the latter, researchers are envisioning culturing a patient’s own adult stem cells to create viable organoids that could be transplanted into the patient with no need for the long-term immunosuppressant drugs they would have taken with a donated organ.

Read more on cellink.com →

“The tissue block, or T-block, is a 3D scaffold that is expandable and modular to grow stem cells. The goal is to efficiently expand a patient’s own stem cells to engineer organoids or grafts that could be used in life-saving surgeries.”

 

A.J. Mellott, PhD

Minimizing the risk of transpant rejection
On-demand Bioprinted Patient-specific Heart Tissue
Dr. Carmine Gentile’s lab in Sydney is developing bioprinted heart tissue on demand with patient-specific cells to minimize the risk of transplant rejection.

There is currently no way to repair damaged heart muscles from heart attacks, so many patients around the world wait on long heart transplant lists. Even for the lucky few who find a matching donor, there are more hurdles (i.e., organ viability, geographical distance, immune rejection). Therefore, heart disease remains the leading cause of death worldwide. According to the World Health Organization, 17.9 million lives are lost each year to cardiovascular diseases.

Dr. Carmine Gentile, leader of the Cardiovascular Regeneration Group at the University of Technology Sydney (UTS), announced in 2020 that his lab had “developed a technology that can 3D model and bioprint personalized hearts for transplantation, using the patient’s own stem cells so that there’s no risk of rejection.” Specifically, the technology identified the optimal conditions for cells to create blood vessels within bioprinted heart patches.

There is currently no way to repair damaged heart muscles from heart attacks, so many patients around the world wait on long heart transplant lists. Even for the lucky few who find a matching donor, there are more hurdles (i.e., organ viability, geographical distance, immune rejection). Therefore, heart disease remains the leading cause of death worldwide. According to the World Health Organization, 17.9 million lives are lost each year to cardiovascular diseases.

Dr. Carmine Gentile, leader of the Cardiovascular Regeneration Group at the University of Technology Sydney (UTS), announced in 2020 that his lab had “developed a technology that can 3D model and bioprint personalized hearts for transplantation, using the patient’s own stem cells so that there’s no risk of rejection.” Specifically, the technology identified the optimal conditions for cells to create blood vessels within bioprinted heart patches.

Read more on cellink.com →

“We are using the patient’s own stem cells so that there’s no risk of rejection.”

 

Dr. Carmine Gentile

Breaking barriers
Printing vascularized skin
Today’s synthetic skin graft products accelerate wound healing but eventually fall off because they never integrate with the patient’s skin tissue. The absence of a functioning vascular system in the synthetic grafts is a significant barrier.

Karande and his team have developed a bioink made up of human endothelial cells, human pericyte cells and animal collagen. They used the CELLINK BIO X and Temperature Controlled Printhead to ensure that these constructs could be printed.

This combination of key elements enabled the cells to start communicating and more importantly begin forming a biologically relevant vascular structure within the span of a few weeks. Once blood vessels formed, nutrients and waste could be exchanged to keep the graft alive. The groups significant development highlights the vast potential of 3D bioprinting in precision medicine, where solutions can be tailored to specific situations.

Karande and his team have developed a bioink made up of human endothelial cells, human pericyte cells and animal collagen. They used the CELLINK BIO X and Temperature Controlled Printhead to ensure that these constructs could be printed.

This combination of key elements enabled the cells to start communicating and more importantly begin forming a biologically relevant vascular structure within the span of a few weeks. Once blood vessels formed, nutrients and waste could be exchanged to keep the graft alive. The groups significant development highlights the vast potential of 3D bioprinting in precision medicine, where solutions can be tailored to specific situations.

Read more on cellink.com →

“…we could potentially even think of using this as a therapy for burn victims.”

 

Pankaj Karande
Associate Professor

Precise and sensitive tools for
COVID-19 monitoring
Given the challenges of combating the COVID-19 pandemic, scientists in both research and diagnostic environments are looking to optimize their workflows for crucial time and cost savings.  

An influential example is a study conducted by Dr. Nicola Crosetto’s lab at Karolinska Institutet, in which the I.DOT (Immediate Drop-on-demand Technology) liquid handler was used to automate and streamline a versatile technique (COVseq) for preparing multiplex DNA sequencing libraries from low-input samples with high accuracy, speed and significant reductions in liquid reagent volumes.

The study revealed that the COVseq technique can be easily applied to ongoing pandemic genomic surveillance and adapted to monitor other pathogens such as influenza viruses. In addition, an analysis of costs showed that the technique could be used to sequence thousands of samples per week at less than $10 per sample, including library preparation and sequencing costs.

An influential example is a study conducted by Dr. Nicola Crosetto’s lab at Karolinska Institutet, in which the I.DOT (Immediate Drop-on-demand Technology) liquid handler was used to automate and streamline a versatile technique (COVseq) for preparing multiplex DNA sequencing libraries from low-input samples with high accuracy, speed and significant reductions in liquid reagent volumes.

The study revealed that the COVseq technique can be easily applied to ongoing pandemic genomic surveillance and adapted to monitor other pathogens such as influenza viruses. In addition, an analysis of costs showed that the technique could be used to sequence thousands of samples per week at less than $10 per sample, including library preparation and sequencing costs.

 

Read more on cellink.com →

“We were able to easily create new workflows for PCR and NGS applications and I highly recommend this system for all labs running high-throughput assays that require complex liquid dispensing schemes, as well as those aiming to lower assay costs by reducing reagent volumes.”

 

Nicola Crosetto, PhD

Water quality analysis
Multiplex tests to detect pathogens and toxins in public water supply

Monitoring the quality of water is of paramount importance for public health. SCIENION’s commitment to develop efficient, sensitive and robust multiplex tests for water quality analysis is reflected by the company’s involvement in various research projects such as microAQUA or “Rheines Wasser”.

In the EU-funded project microAQUA, twelve partners from eight countries collaborated to develop universal microarrays for the evaluation of fresh-water quality. MicroAQUA aimed to design and develop a microarray chip for the high-throughput detection of known and emerging pathogens (bacteria, viruses, protozoa and cyanobacteria) and to assess the water quality by monitoring the presence of select bioindicators such as diatoms.

The company developed the microarrays and provided the infrastructure and expertise for the production of the arrays and their analysis. This microarray was used for the analysis of the RNA extracted from environmental samples collected from fresh, brackish, marine and drinking water from different locations in six countries (Bulgaria, France, Germany, Ireland, Italy and Turkey).

In the EU-funded project microAQUA, twelve partners from eight countries collaborated to develop universal microarrays for the evaluation of fresh-water quality. MicroAQUA aimed to design and develop a microarray chip for the high-throughput detection of known and emerging pathogens (bacteria, viruses, protozoa and cyanobacteria) and to assess the water quality by monitoring the presence of select bioindicators such as diatoms.

 

The company developed the microarrays and provided the infrastructure and expertise for the production of the arrays and their analysis. This microarray was used for the analysis of the RNA extracted from environmental samples collected from fresh, brackish, marine and drinking water from different locations in six countries (Bulgaria, France, Germany, Ireland, Italy and Turkey).

 

Read more on scienion.com →

“A key step on the preparation of the biochip is printing the microarray; here we can produce hundreds of small spots, less than a millimeter in diameter. The great advantage of this method is that we can get an answer almost immediately; in a day we can detect up to 150 different species in the water.”

 

Dr. Wilfried Weigel, VP of R&D at SCIENION

Getting personal
Carcinotech is bioprinting patient-specific tumor models for individualized drug testing

To address the need for personalized oncology drug testing, CEO Ishani Malhotra founded Carcinotech, the Edinburgh-based biotech that is bioprinting patient-specific testing models with cells from biopsy samples. Find out how these ingenious researchers benefited from expert support from CELLINK, a BICO company.

 

Why is Breast Cancer Awareness month important to you?

The annual breast cancer awareness campaign helps women and men (who also suffer from breast cancer) understand the importance of self-checking and scheduling lab tests to catch the disease early. Breast Cancer Awareness Month is also a chance to highlight the amazing progress researchers are making to develop more treatments options for breast cancer.

Why is Breast Cancer Awareness month important to you?

The annual breast cancer awareness campaign helps women and men (who also suffer from breast cancer) understand the importance of self-checking and scheduling lab tests to catch the disease early. Breast Cancer Awareness Month is also a chance to highlight the amazing progress researchers are making to develop more treatments options for breast cancer.

Read full story on cellink.com →

Breast cancer construct

“Carcinotech’s testing model also makes it possible to screen thousands of potential cancer drug compounds in a high-throughput manner, with disease models that more accurately replicate human tissue and minimize the use of animals for preclinical testing”

 

Ishani Malhotra, CEO Carcinotech